Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | Complement component 5 |
Clinical data | |
Pronunciation | rav" ue liz' ue mab |
Trade names | Ultomiris |
Other names | ALXN1210, ravulizumab-cwvz |
AHFS/Drugs.com | Monograph |
MedlinePlus | a619014 |
License data |
|
Pregnancy category |
|
Routes of administration | Intravenous |
Drug class | Complement inhibitor |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | various proteases |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6430H9888N1696O2028S48 |
Molar mass | 144938.56 g·mol−1 |
Ravulizumab, sold under the brand name Ultomiris, is a humanized monoclonal antibody complement inhibitor medication designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. It is designed to bind to and prevent the activation of Complement component 5 (C5).[8][7]
Paroxysmal nocturnal hemoglobinuria is characterized by red blood cell destruction, anemia (red blood cells unable to carry enough oxygen to tissues), blood clots, and impaired bone marrow function (not making enough blood cells).[9] In paroxysmal nocturnal hemoglobinuria, proteins known as the 'complement system', which is part of the immune system, become overactive because of a genetic mutation and start to attack the patients' own red blood cells.[8] Ravulizumab, is a monoclonal antibody (a type of protein) designed to attach to the C5 protein, which is part of the complement system.[8] By attaching to the C5 protein, the medicine blocks its effect and thereby reduces the destruction of red blood cells.[8]
Ultomiris EPAR
was invoked but never defined (see the help page).FDA PR 20210607
was invoked but never defined (see the help page).